OpGen (OPGN) Peer Comparison
$0.33
$-2.07
(-86.38%)
As on 12-May-2026 09:30EDT
Market cap
$251 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
137.5
P/B Ratio
0
Div. Yield
0 %
Edit
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
Market cap ($ Mln) |
251 | 6,732 | 6,117 | 1,728 |
Revenue ($ Mln) |
5 | 22 | -- | -- |
Net Profit ($ Mln) |
11.99 | -228.93 | -96.21 | -235.09 |
Net Margin (%) |
-87.52 | -1,027.25 | -- | -- |
RoE (%) |
162.49 | -53.42 | -14.23 | -90.96 |
Price to Earnings |
137.50 | -- | -- | -- |
Price-To-Book |
0.00 | 16.73 | 6.08 | 163.79 |
Income Statement ($ Mln)
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Operating Revenue
|
30.20 | 22.29 | 0.00 | 0.00 |
|
Cost of Revenue
|
3.02 | 6.68 | -- | 0.03 |
|
Gross Profit
|
27.18 | 15.61 | -- | -0.03 |
|
Operating Expenses
|
3.15 | 268.69 | 110.12 | 210.87 |
|
Operating Profit (EBIT)
|
24.03 | -253.08 | -110.12 | -210.87 |
|
Other Income
|
-- | -- | -- | -- |
|
Profit before Tax
|
24.43 | -228.87 | -95.63 | -209.79 |
|
Provision for Tax
|
-0.81 | 0.07 | 0.58 | 0.05 |
|
Profit after Tax (Net Income)
|
23.62 | -228.93 | -96.21 | -209.84 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- |
Liabilities ($ Mln)
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
31.86 | 402.35 | 1,006.52 | 240.38 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
1.65 | 97.44 | 2.14 | 0.08 |
|
Current Liabilities
|
4.55 | 104.20 | 16.41 | 20.07 |
|
Total Liabilities
|
38.06 | 603.99 | 1,025.08 | 260.53 |
Assets ($ Mln)
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Non-Current Assets
|
37.07 | 141.81 | 0.88 | 0.10 |
|
Current Assets
|
0.99 | 462.18 | 1,024.19 | 260.42 |
|
Total Assets
|
38.06 | 603.99 | 1,025.08 | 260.53 |
|
Total Debt*
|
1.85 | 96.26 | 0.92 | 0.07 |
|
Net Current Assets
|
-- | 357.98 | 1,007.78 | 240.36 |
Cashflow ($ Mln)
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.18 | -210.26 | -82.18 | -6.73 |
|
Cash Flow from Investing Activities
|
-0.05 | 86.30 | -298.04 | -17.37 |
|
Cash from Financing Activities
|
0.50 | 98.53 | 743.51 | 266.84 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
ROCE (%)
|
114.98 | -45.45 | -14.20 | -163.71 |
|
ROE (%)
|
120.40 | -53.42 | -14.23 | -163.80 |
|
ROA (%)
|
98.59 | -34.81 | -13.85 | -151.15 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
78.21 | -1,027.25 | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
4.81 | -0.79 | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
96.95 | -113.26 | -8.28 | -878.77 |
|
EPS Growth (%)
|
0.97 | -1.03 | -0.06 | -6.09 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Price / Earnings
|
-- | -16.04 | -39.12 | -0.18 |
|
Price / Book Value
|
-- | 9.12 | 3.74 | 0.15 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-- | -16.76 | -24.93 | 1.05 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.06 | 0.24 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.02 | 0.00 | 0.00 |
|
Current Ratio
|
0.22 | 4.44 | 62.41 | 12.98 |
|
Quick Ratio
|
-- | -- | -- | -- |
|
Interest Coverage
|
0.00 | -8.45 | -- | -- |
Operating Efficiency Ratios
| OpGen (OPGN) | Arcellx Inc (ACLX) | Terns Pharmaceuticals (TERN) | Galecto Inc (GLTO) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
0.82 | 16.15 | -- | -- |
|
Asset Turnover
|
1.26 | 0.03 | 0.00 | 0.00 |
|
Receivable days
|
1.68 | 59.00 | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- |
|
Payable days
|
80.25 | 209.78 | -- | 4,409.86 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
